PREVENTION OF EXPERIMENTAL CORONAVIRUS COLDS WITH INTRANASAL ALPHA-2B INTERFERON
PREVENTION OF EXPERIMENTAL CORONAVIRUS COLDS WITH INTRANASAL ALPHA-2B INTERFERON
复制标题
DOI：
10.1093/infdis/154.3.443
复制
发表时间：
1986-09-01
影响因子：
6.4
通讯作者：
MESCHIEVITZ, CK
中科院分区：
文献类型：
--
作者：
TURNER, RB;FELTON, A;MESCHIEVITZ, CK
55名志愿者用鼻内重组干扰素（rIFN; 2 × 10 - 6）或鼻内重组干扰素（rIFN; 2 × 10 - 6）治疗。106 IU/天）或安慰剂15天，在治疗的第8天通过直接鼻内接种暴露于冠状病毒。记录症状评分，并在接种后7天内每天对所有志愿者进行病毒培养。26名安慰剂接受者中有19名（73%）符合感冒的评分标准，而干扰素接受者中有12名（41%）符合（P = 0.02）。安慰剂组和干扰素组的平均鼻部症状评分分别为9.2和5.4（P = .03），两组的平均总症状评分分别为23.2和9.4（P = .003）。总症状评分> 4的平均天数在安慰剂接受者中为1.6，在rIFN接受者中为0.5（P = 0.02）。预防性鼻内rIFN有效地缩短了冠状病毒感冒症状的持续时间并降低了其严重程度。
Fifty-five volunteers treated with either intranasal recombinant interferon (rIFN; 2 .times. 106 IU/day) or placebo for 15 days were exposed to coronavirus by direct intranasal inoculation on the eighth day of treatment. Symptom scores were recorded, and cultures of virus were taken daily for all volunteers for seven days after inoculation. Nineteen (73%) of the 26 placebo recipients met symptom-score criteria for a cold, compared with 12 (41%) of the IFN recipients (P = .02). The mean nasal symptom scores in the placebo and IFN groups were 9.2 and 5.4, respectively (P = .03), and the mean total symptom scores in the two groups were 23.2 and 9.4, respectively (P = .003). The mean number of days with a total symptom score > 4 was 1.6 in the placebo recipients and 0.5 in the rIFN recipients (P = .02). Prophylactic intranasal rIFN effectively shortened the duration and reduced the severity of coronavirus cold symptoms.